Global Venous Thromboembolism Therapeutics Market 2017-2021

  • ID: 4115347
  • Report
  • Region: Global
  • 82 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Altor Bioscience
  • Bayer HealthCare
  • Boehringer Ingelheim
  • Gamma Therapeutics
  • Isis Pharmaceutical
  • Pfizer
  • MORE
About Venous Thromboembolism Therapeutic

The global VTE therapeutics market is expected to benefit from the growing incidence of VTE worldwide. According to the CDC, every year around 0.9 million individuals are affected by VTE in the US and 60,000 to 100,000 individuals in the US die of VTE. Further, the presence of high unmet medical needs is expected to fuel the market growth. For instance, according to the CDC approximately 50% of individuals with VTE will have long-term complications, and 33% of individuals will have a recurrence within ten years.

The analysts forecast the global venous thromboembolism therapeutic market to grow at a CAGR of 6.40% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global venous thromboembolism therapeutic market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of VTE products in the following drug classes.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Venous Thromboembolism Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
- Bayer HealthCare
- BMS
- Boehringer Ingelheim
- Daiichi Sankyo
- Johnson & Johnson
- Sanofi

Other prominent vendors
- Altor Bioscience
- Armetheon
- Aspen Pharma
- BioInvent International
- eXIthera Pharmaceuticals
- Gamma Therapeutics
- GlycoMimetics
- Green Cross
- Isis Pharmaceutical
- Leo Pharma
- Pfizer
- Portola Pharmaceuticals
- ThromboGenics

Market drivers
- Increasing surgical procedures such as hip and knee replacements.
- For a full, detailed list, view the full report

Market challenges
- Presence of alternatives such as thrombectomy and percutaneous techniques.
- For a full, detailed list, view the full report

Market trends
- Development of drugs for new indications.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Altor Bioscience
  • Bayer HealthCare
  • Boehringer Ingelheim
  • Gamma Therapeutics
  • Isis Pharmaceutical
  • Pfizer
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

Highlights

PART 05: Disease overview

Diagnosis of VTE

Treatment of VTE

PART 06: Pipeline analysis

PART 07: Market landscape

Market overview

Five forces analysis

PART 08: Market segmentation by drug class

Factor Xa inhibitors

Direct thrombin inhibitors

Heparin

Vitamin K antagonists

PART 09: Geographical segmentation

VTE therapeutics market in Americas

VTE therapeutics market in EMEA

VTE therapeutics market in APAC

PART 10: Market drivers

Increasing adoption of NOACs

Increasing surgical procedures such as hip and knee replacements

Large patient pool coupled with growing awareness campaigns

PART 11: Impact of drivers

PART 12: Market challenges

Presence of alternatives such as thrombectomy and percutaneous techniques

Unmet needs for anticoagulant reversal agents

Extensive use of generic products

PART 13: Impact of drivers and challenges

PART 14: Market trends

Development of drugs for new indications

Growing focus on emerging economies

Patient assistance programs

PART 15: Vendor landscape

Competitive scenario

PART 16: Key vendor analysis

Bayer HealthCare

BMS

Boehringer Ingelheim

Daiichi Sankyo

Johnson & Johnson

Sanofi

Other prominent vendors

PART 17: Appendix

List of abbreviations

PART 18: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Types of venous thromboembolism
Exhibit 03: Pipeline analysis
Exhibit 04: Key pipeline molecules
Exhibit 05: Global VTE therapeutics market snapshot
Exhibit 06: Global VTE therapeutics market 2016-2021 ($ millions)
Exhibit 07: Opportunity analysis in global venous thromboembolism market
Exhibit 08: Five forces analysis
Exhibit 09: Factor Xa inhibitors in global VTE therapeutics market 2016-2021 ($ millions)
Exhibit 10: Direct thrombin inhibitors in venous thromboembolism market 2016-2021 ($ millions)
Exhibit 11: Heparin in global VTE therapeutics market 2016-2021 ($ millions)
Exhibit 12: Vitamin K antagonists in global venous thromboembolism market 2016-2021 ($ millions)
Exhibit 13: Segmentation of global VTE therapeutics market based on geography 2016 and 2021
Exhibit 14: VTE therapeutics market revenue by geography 2016-2021 (%)
Exhibit 15: Market scenario in Americas
Exhibit 16: VTE therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 17: Market scenario in EMEA
Exhibit 18: VTE therapeutics market in EMEA ($ millions)
Exhibit 19: Market scenario in APAC
Exhibit 20: Venous thromboembolism therapeutics market in APAC ($ millions)
Exhibit 21: Impact of drivers
Exhibit 22: Forcefield analysis of drivers and challenges
Exhibit 23: Impact of drivers and challenges
Exhibit 24: Competitive structure analysis of global VTE therapeutics market 2015
Exhibit 25: Competitive analysis of global VTE therapeutics market 2016
Exhibit 26: Market share analysis 2015
Exhibit 27: Market penetration of various VTE manufacturers worldwide 2016
Exhibit 28: Strategic success factors of companies in global VTE therapeutics market
Exhibit 29: Bayer HealthCare: Key highlights
Exhibit 30: Bayer HealthCare: Strength assessment
Exhibit 31: Bayer HealthCare: Strategy assessment
Exhibit 32: Bayer HealthCare: Opportunity assessment
Exhibit 33: Bayer HealthCare: YoY revenue and growth rate of Xarelto 2013-2015 ($ billions)
Exhibit 34: BMS: Key highlights
Exhibit 35: BMS: Strength assessment
Exhibit 36: BMS: Strategy assessment
Exhibit 37: BMS: Opportunity assessment
Exhibit 38: BMS: YoY revenue and growth rate of Eliquis (outside the US) 2013-2015 ($ millions)
Exhibit 39: Geographic segmentation of Eliquis 2015
Exhibit 40: Boehringer Ingelheim: Key highlights
Exhibit 41: Boehringer Ingelheim: Strength assessment
Exhibit 42: Boehringer Ingelheim: Strategy assessment
Exhibit 43: Boehringer Ingelheim: Opportunity assessment
Exhibit 44: Boehringer Ingelheim: YoY revenue and growth rate of Pradaxa (Global) 2013-2015 ($ billions)
Exhibit 45: Daiichi Sankyo: Key highlights
Exhibit 46: Daiichi Sankyo: Strength assessment
Exhibit 47: Daiichi Sankyo: Strategy assessment
Exhibit 48: Daiichi Sankyo: Opportunity assessment
Exhibit 49: Johnson & Johnson: Key highlights
Exhibit 50: Johnson & Johnson: Strength assessment
Exhibit 51: Johnson & Johnson: Strategy assessment
Exhibit 52: Johnson & Johnson: Opportunity assessment
Exhibit 53: Johnson & Johnson: YoY revenue and growth rate of Xarelto 2013-2015 ($ millions)
Exhibit 54: Sanofi: Key highlights
Exhibit 55: Sanofi: Strength assessment
Exhibit 56: Sanofi: Strategy assessment
Exhibit 57: Sanofi: Opportunity assessment
Exhibit 58: Sanofi: YoY revenue and growth rate of Lovenox 2013-2015 ($ billions)
Exhibit 59: Geographical segmentation of Lovenox 2015
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Altor Bioscience
  • Bayer HealthCare
  • Boehringer Ingelheim
  • Gamma Therapeutics
  • Isis Pharmaceutical
  • Pfizer
  • MORE
New Report Released: – Global Venous Thromboembolism Therapeutic Market 2017-2021

The author of the report recognizes the following companies as the key players in the global venous thromboembolism therapeutic market: Bayer HealthCare, BMS, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, and Sanofi.

Other Prominent Vendors in the market are: Altor Bioscience, Armetheon, Aspen Pharma, BioInvent International, eXIthera Pharmaceuticals, Gamma Therapeutics, GlycoMimetics, Green Cross, Isis Pharmaceutical, Leo Pharma, Pfizer, Portola Pharmaceuticals, and ThromboGenics.

Commenting on the report, an analyst from the research team said: “One trend in market is development of drugs for new indications. The development of drugs for new indications will improve the sources of revenue generation and will likely drive the market growth. The vendors are extensively conducting research to develop drugs for hospitalized acute medically ill patients having risk of VTE. Till date, there is no approved drug for such patients. Therefore, many vendors such as Portola Pharmaceuticals are focusing on addressing that untapped market to drive growth and profitability. For instance, in October 2016, Portola Pharmaceuticals submitted a NDA to the US FDA seeking marketing approval for betrixaban, (currently in later stage of phase III) for the extended-duration prophylaxis of VTE in acute medically ill individuals with risk factors for VTE.”

According to the report, one driver in market is increasing surgical procedures such as hip and knee replacements. The increasing surgical procedures such as hip and knee replacements will increase the risk of DVT, thereby driving the market growth. Joint replacement surgeries often result in long periods of immobility, increasing the chances of developing DVT due to reduced blood flow. As per CDC, over a million Americans undergo joint replacement surgeries every year. Individuals undergoing knee replacement and hip replacement surgeries have an increased likelihood of developing DVT.

Further, the report states that one challenge in market is presence of alternatives such as thrombectomy and percutaneous techniques. The presence of alternative treatment approaches such as thrombectomy and percutaneous techniques are expected to hinder growth prospects in the market. For instance, thrombectomy was performed to boost the venous outflow from the leg, while femoral vein ligation was preferred to prevent subsequent PE. Surgical thrombectomy is reserved for individuals, with contraindications to pharmacological thrombolysis or in whom the other modalities have failed. Later, the advent of pharmacological thrombolysis has further increased the substitute therapies in the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Bayer HealthCare
  • BMS
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • Johnson & Johnson
  • Sanofi
  • Altor Bioscience
  • Armetheon
  • Aspen Pharma
  • BioInvent International
  • eXIthera Pharmaceuticals
  • Gamma Therapeutics
  • GlycoMimetics
  • Green Cross
  • Isis Pharmaceutical
  • Leo Pharma
  • Pfizer
  • Portola Pharmaceuticals
  • ThromboGenics
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll